Literature DB >> 12124449

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.

Paul P Heinen1, Frans A Rijsewijk1, Els A de Boer-Luijtze1, André T J Bianchi1.   

Abstract

In mice, vaccines inducing antibodies to the extracellular domain of the M2 protein (M2e) can confer protection to influenza A virus infection. Unlike the surface glycoproteins, haemagglutinin and neuraminidase, this domain of M2 is highly conserved and is therefore a potential broad-spectrum immunogen. In this study, the protection conferred by vaccines inducing antibodies to M2e was evaluated in a challenge model for swine influenza in pigs. A protein resulting from the fusion between M2e and the hepatitis B virus core protein (M2eHBc), with or without adjuvant, was evaluated. In addition, a DNA construct expressing a fusion protein between M2e and influenza virus nucleoprotein (M2eNP) was evaluated to see if the broad-spectrum protection conferred by antibodies could be further enhanced by T helper cells and cytotoxic T cells. All vaccines induced an antibody response against M2e, and the M2eNP DNA vaccine additionally induced an influenza virus-specific lymphoproliferation response. However, after challenge with a swine influenza virus (H1N1), no protection was observed in the vaccinated groups compared with the non-vaccinated control group. On the contrary, vaccinated pigs showed more severe clinical signs than the control pigs. The M2eNP DNA-vaccinated pigs showed the most severe clinical signs and three out of six pigs died on days 1 and 2 post-challenge. These results indicate that antibodies to M2e, especially in combination with cell-mediated immune responses, exacerbate disease. Thus, clinical signs after infection should be observed closely in further studies using M2e as an immunogen and caution should be exercised in using M2e in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124449     DOI: 10.1099/0022-1317-83-8-1851

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  61 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

Review 2.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

3.  Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine.

Authors:  Jürgen A Richt; Porntippa Lekcharoensuk; Kelly M Lager; Amy L Vincent; Christina M Loiacono; Bruce H Janke; Wai-Hong Wu; Kyoung-Jin Yoon; Richard J Webby; Alicia Solórzano; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.

Authors:  Dongming Zhou; Te-Lang Wu; Marcio O Lasaro; Brian P Latimer; Elizabeth M Parzych; Ang Bian; Yan Li; Hua Li; Jan Erikson; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

5.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

Review 6.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

Review 7.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

Authors:  James E Crowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

8.  Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Authors:  Min-Chul Kim; Yu-Na Lee; Eun-Ju Ko; Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Jae-Min Song; Byung-Min Song; Youn-Jeong Lee; Jun-Gu Choi; Hyun-Mi Kang; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2014-03-04       Impact factor: 11.454

9.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

Review 10.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.